Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for schizophrenia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. An oral compound, SEP-363856, that does not act on dopamine D2 receptors but has agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptors, may represent a new class of psychotropic agent for the treatment of psychosis in schizophrenia.We performed a randomized, controlled trial to evaluate the efficacy and safety of SEP-363856 in adults with an acute exacerbation (...) of schizophrenia. The patients were randomly assigned in a 1:1 ratio to receive once-daily treatment with SEP-363856 (50 mg or 75 mg) or placebo for 4 weeks. The primary end point was the change from baseline in the total score on the Positive and Negative Symptom Scale (PANSS; range, 30 to 210; higher scores indicate more severe psychotic symptoms) at week 4. There were eight secondary end points, including the changes from baseline in the scores on the Clinical Global Impressions Severity (CGI-S) scale
Lumateperone tosylate (Caplyta) - schizophrenia Drug Approval Package: CAPLYTA CAPLYTA " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: CAPLYTA Company: Intra-Cellular Therapies, Inc Application Number: 209500 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Treatment of Patients with Schizophrenia This guideline is undergoing copyediting and the final version is expected to be released summer 2020. THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA Guideline Writing Group George A. Keepers, M.D. (Chair) Laura J. Fochtmann, M.D., M.B.I. (Vice-Chair; Methodologist) Joan M. Anzia, M.D. Sheldon Benjamin, M.D. Jeffrey M. Lyness, M.D. Ramin Mojtabai, M.D. Mark Servis, M.D. Art Walaszek, M.D. Peter (...) Schizophrenia 18 Implementation 18 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 31 Review of Available Guidelines from Other Organizations 32 Quality Measurement Considerations 32 Statement 2: Use of Quantitative Measures 33 Implementation 33 Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement 36 Review of Available Guidelines from Other Organizations 38 Quality Measurement Considerations 38 Statement 3: Evidence-based
Evidence-based guidelines for the pharmacological treatment of schizophrenia The British Association for Psychopharmacology | BAP Consensus Guidelines – Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Email Address: Password: Keep me logged in for 24 hours | Menu About Us Join BAP Members' Area Publications Meetings Education and Training Prizes and Awards Prizes and Awards Bursaries (...) > > Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology Please note that COPYRIGHT in the paper is owned by the British Association for Psychopharmacology (BAP). SINGLE ISSUE USE ONLY (and printing) for PERSONAL RESEARCH ONLY is acceptable. Information
Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear.To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients (...) with schizophrenia and predominant negative symptoms.The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included.Ten sessions of tDCS performed twice
Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Atypical Injectable Antipsychotics for Schizophrenia (...) or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: January 3, 2019 Project Number: RC1053-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients with schizophrenia or bipolar disorder? What is the cost-effectiveness of atypical long-acting injectable antipsychotics for the treatment of patients
Acetylsalicylic acid (aspirin) for schizophrenia. Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia. Antipsychotic drugs are the conventional treatment for people with schizophrenia but are not always fully effective. Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) with properties that inhibit (...) the proinflammatory status of the brain. Using aspirin as an adjunct (add-on) treatment to antipsychotics or as a stand-alone treatment could be a novel, relatively inexpensive option for people with schizophrenia.To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (last search 8 March 2018) which is based on regular searches of MEDLINE, Embase, PubMed, CINAHL, BIOSIS
Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental illnesses. People with catatonia are more likely to require hospitalisation and highly supervised care than those without the disorder. They also have an increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug (...) therapies and electroconvulsive therapy.To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for catatonia in people with schizophrenia or other similar serious mental illnesses (SMIs).We updated our previous search (28 February 2007) by searching the Cochrane Schizophrenia Group's Study-Based Register of Trials (9 November 2016; 6 February 2019). This register is compiled by systematic searches of major resources (including CENTRAL, MEDLINE, Embase, AMED
Brexpiprazole (Rxulti) for the treatment of schizophrenia in adults Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults | Report | National Health Care Institute You are here: Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Search within English part of National Health Care Institute Search Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti® (...) ) can be accepted into the Medicine Reimbursement System (GVS). Registration Brexpiprazole (Rxulti®), an antipsychotic, is registered and indicated for the treatment of schizophrenia in adults. Zorginstituut's advice Based on the criteria for interchangeability, we conclude that brexpiprazole (Rzulti®) is interchangeable with the other drugs in GVS cluster N405AXAO V, which includes: aripiprazole, cariprazine, paliperidone, quetiapine and risperidone. A standard dose of 3 mg can be established
Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Schizophrenia is a leading cause of disability, and a shift from facility- to community-based care has been proposed to meet the resource challenges of mental healthcare in low- and middle-income countries. We hypothesized that the addition of mobile texting would improve (...) schizophrenia care in a resource-poor community setting compared with a community-based free-medicine program alone.In this 2-arm randomized controlled trial, 278 community-dwelling villagers (patient participants) were randomly selected from people with schizophrenia from 9 townships of Hunan, China, and were randomized 1:1 into 2 groups. The program participants were recruited between May 1, 2015, and August 31, 2015, and the intervention and follow-up took place between December 15, 2015, and July 1
Cariprazine (Reagila) for the treatment of schizophrenia in adult patients. 1 Published 13 May 2019 1 SMC2137 cariprazine 1.5mg, 3mg, 4.5mg and 6mg hard capsules (Reagila®) Recordati Pharmaceuticals Ltd 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission cariprazine (Reagila® (...) ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of schizophrenia in adult patients. SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature. In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic. Chairman Scottish Medicines Consortium www.scottishmedicines.or g.uk 2
Haloperidol discontinuation for people with schizophrenia. Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews.To review the effects of haloperidol discontinuation (...) in people with schizophrenia who are stable on haloperidol.On 20 February 2015, 24 May 2017, and 12 January 2019, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including trial registers.We included clinical trials randomising adults with schizophrenia or related disorders who were receiving haloperidol, and were stable. We included trials that randomised such participants to either continue their current treatment with haloperidol or discontinue their haloperidol
Yoga as part of a package of care versus non-standard care for schizophrenia. Yoga is an ancient body-mind practice which originated in India and is popular in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine the efficacy of yoga delivered as a package of care versus non-standard care.To examine the effects of yoga as part of a package of care versus non-standard care for schizophrenia.We searched the Cochrane (...) Schizophrenia Group Trials Register (latest 15 May 2018) which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSS, AMED, PsychINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga as part of a package of care with non-standard care.There were
Schizophrenia TreAtment with electRic Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial. Schizophrenia is a severe mental disorder. While some antipsychotic medications have demonstrated efficacy in treating positive symptoms, there is no widely recognized treatment for negative symptoms, which can cause significant distress and impairment for patients with schizophrenia. Here we describe the rationale and design (...) of the STARTS study (Schizophrenia TreAtment with electRic Transcranial Stimulation), a clinical trial aimed to test the efficacy of a non-pharmacological treatment known as transcranial direct current stimulation (tDCS) for treating the negative symptoms of schizophrenia.The STARTS study is designed as a randomized, sham-controlled, double-blinded trial evaluating tDCS for the treatment of the negative symptoms of schizophrenia. One-hundred patients will be enrolled and submitted to 10 tDCS sessions over
Music Therapy as Treatment of Negative Symptoms for Adult Patients Diagnosed with Schizophrenia-Study Protocol for a Randomized, Controlled and Blinded Study. Background: Three Cochrane reviews show that music therapy has a positive effect on schizophrenia concerning general functioning and positive/negative symptoms. This study aims to replicate these results in the Danish health system, a requirement for recommendation in guidelines from the Danish National Board of Health. Methods: The study (...) is a randomized, controlled multi-site study, with a blinded design, aiming to include 90 participants who are 18⁻65 years in age, diagnosed according to ICD-10 with a schizophrenia diagnosis. The participants are randomized to one of two different music therapy activities for 25 weekly sessions. The study interventions are added to standard care. Outcome measures are rated at baseline, after 15 sessions and post therapy. A qualitative interview is performed as a one month follow up at the end of study
Pharmacological interventions: Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) | Evidence-Based Mental Health Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Article Text Commentary Pharmacological interventions Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Marco Solmi 1 , 2 , Christoph U Correll 3 , 4 , 5 , 6 Statistics from Altmetric.com Commentary
Adherence therapy for schizophrenia: a randomised controlled trial. 30674700 2019 01 24 1024-2708 25 Suppl 2 2019 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Adherence therapy for schizophrenia: a randomised controlled trial. 4-9 Chien W T WT Nethersole School of Nursing, The Chinese University of Hong Kong. Cheung E Fc EF Castle Peak Hospital, Hospital Authority, Hong Kong. Mui J Hc JH Castle Peak Hospital, Hospital Authority, Hong Kong. Gray R R Faculty of Medicine
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial Obesity is a major challenge for people with schizophrenia.AimsWe assessed whether STEPWISE, a theory-based, group structured lifestyle education programme could support weight reduction in people with schizophrenia.In this randomised controlled trial (study registration: ISRCTN19447796), we recruited adults with schizophrenia
Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder Patients with schizophrenia or bipolar disorder have a high risk of developing type 2 diabetes.To identify predictive factors for hyperglycaemic progression in individuals with schizophrenia or bipolar disorder and to determine whether hyperglycaemic progression rates differ among antipsychotics in regular clinical practice.We recruited 1166 patients who initially had normal or prediabetic
Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacistâ€“physician collaboration in the outpatient department Cognitive impairment is a core feature and shows the highest impact on functional outcome in patients with schizophrenia. There have been no previous studies investigating the role of the pharmacist in a multidisciplinary team on cognitive outcomes in patients with schizophrenia.We evaluated the impact of pharmacist intervention on cognitive (...) outcomes in patients with schizophrenia by focusing on anticholinergic discontinuation.A prospective, open-label, randomized, controlled study was conducted. Patients with schizophrenia were randomly assigned to either the pharmacist intervention or usual care groups. In the pharmacist intervention group, the pharmacist identified drug-related problems (DRPs) and provided a pharmacotherapy suggestion, while there was no intervention in the usual care group. The primary outcome was mean change from